Immunoglobulin G1 (IgG1) is a type of antibody that plays a crucial role in the immune response by recognizing and binding to specific antigens. The substance in question, a dimeric form of mouse monoclonal antibody CC49, is engineered to target human tumor-associated glycoprotein 72 (TAG-72), which is often overexpressed in certain cancers, particularly colorectal cancer. This dimer consists of two distinct chains: a γ1 heavy chain and a κ light chain, linked by disulfide bonds, which stabilize the structure and enhance its functionality. The specificity of this antibody allows for potential applications in targeted therapy and diagnostic imaging in oncology. Additionally, the dimeric nature of the antibody may improve its binding affinity and therapeutic efficacy compared to its monomeric counterparts. Overall, this compound exemplifies the use of monoclonal antibodies in cancer treatment, leveraging their ability to selectively bind to tumor markers while minimizing effects on normal tissues.

Immunoglobulin G1, anti-(human tumor-associated glycoprotein 72) (mouse monoclonal Mab CC49 γ1-chain) disulfide with mouse monoclonal Mab CC49 κ-chain, dimer

195189-17-4: Immunoglobulin G1 (IgG1) is a type of antibody that plays a crucial role in the immune response by recognizing and binding to specific antigens. The substance in question, a dimeric form of mouse monoclonal antibody CC49, is engineered to target human tumor-associated glycoprotein 72 (TAG-72), which is often overexpressed in certain cancers, particularly colorectal cancer. This dimer consists of two distinct chains: a γ1 heavy chain and a κ light chain, linked by disulfide bonds, which stabilize the structure and enhance its functionality. The specificity of this antibody allows for potential applications in targeted therapy and diagnostic imaging in oncology. Additionally, the dimeric nature of the antibody may improve its binding affinity and therapeutic efficacy compared to its monomeric counterparts. Overall, this compound exemplifies the use of monoclonal antibodies in cancer treatment, leveraging their ability to selectively bind to tumor markers while minimizing effects on normal tissues.

Anti-human tumor-associated glycoprotein 72 (TAG72) mouse monoclonal antibody.

Minretumomab

Minretumomab (CC-49) is a mouse monoclonal antibody targeting TAG-72 breast cancer, colon cancer, lung cancer, and pancreatic cancer.

CAS 195189-17-4

Immunoglobulin G1, anti-(human tumor-associated glycoprotein 72) (mouse monoclonal Mab CC49 γ1-chain) disulfide with mouse monoclonal Mab CC49 κ-chain, dimer

Minretumomab

Ref: 3D-CLA1231

Minretumomab

Ref: TM-T81793